Archiv
Archiv anzeigen:
bis


Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulopathy

Brady L. Stein, MD, MHS reviewing Iba T et al. J Thromb Haemost 2019 Jul 20

An expert panel proposes a new category — sepsis-induced coagulopathy — as a preceding phase prior to overt disseminated intravascular coagulopathy.


Resection of Cavity Shave Margins in Breast Conserving Surgery

Henry Mark Kuerer, MD, PhD, FACS reviewing Dupont E et al. Ann Surg 2019 Jul 8

Resection of additional tissue around the tumor cavity significantly reduces the need to return to surgery for margin control.


PET-Adapted Treatment for Hodgkin Lymphoma

Michael E. Williams, MD, ScM reviewing Barrington SF et al. J Clin Oncol 2019 Jul 10

The highest PET score following three cycles of induction chemotherapy was associated with poor outcomes in patients with early-stage disease.


Incidental Pulmonary Embolism in Cancer Patients

Brady L. Stein, MD, MHS reviewing Kraaijpoel N et al. J Clin Oncol 2019 Jul 10

Patients with incidental PE, including those with subsegmental involvement, had increased recurrence rates, despite treatment.


Another Antibody Drug Conjugate for Breast Cancer?

William J. Gradishar, MD reviewing Banerji U et al. Lancet Oncol 2019 Jun 27

In a phase I study, trastuzumab duocarmazine demonstrated antitumor activity with manageable toxicity in HER2-low breast cancers and other solid tumors.


Frontline Daratumumab for Transplant-Eligible Myeloma Patients

Michael E. Williams, MD, ScM reviewing Moreau P et al. Lancet 2019 Jul 6, Hofmeister CC et al. Lancet 2019 Jul 6

Outcomes were improved when daratumumab was combined with induction therapy prior to stem-cell transplant consolidation.


Venetoclax plus Obinutuzumab for Chronic Lymphocytic Leukemia

Michael E. Williams, MD, ScM reviewing Fischer K et al. N Engl J Med 2019 Jun 6

Outcomes were improved compared with standard chlorambucil plus obinutuzumab in previously untreated CLL patients with coexisting conditions.


Frontline Immunotherapy for Myeloma

Michael E. Williams, MD, ScM reviewing Facon T et al. N Engl J Med 2019 May 30

Daratumumab added to lenalidomide-plus-dexamethasone improved outcomes in newly diagnosed patients.


Ibrutinib plus Venetoclax for Chronic Lymphocytic Leukemia

Michael E. Williams, MD, ScM reviewing Jain N et al. N Engl J Med 2019 May 30

The combination therapy provided a high remission rate in previously untreated older and high-risk patients.


Fractionated Radiotherapy for Prostate Cancer: Current Status

Robert Dreicer, MD, MS, MACP, FASCO reviewing Widmark A et al. Lancet 2019 Jun 18, Catton C and Lukka H. Lancet 2019 Jun 18

An ultra-hypofractionated approach was found noninferior to conventional hypofractionation but was accompanied by more urinary-tract and bowel symptoms.


Archiv
Seite von 83
Editorial Member Board Empfehlungen

Prof. Dr. med. Christoph Rochlitz

Chefarzt Onkologie
Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.

Kommentar weiterlesen

Apalutamide for Castration-Resistant PSA-Only Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Smith MR et al. N Engl J Med 2018 Feb 8

Metastasis-free survival was significantly longer with apalutamide than with placebo.


Second-Line Olaparib for Gastric Cancer

David H. Ilson, MD, PhD reviewing Bang Y-J et al. Lancet Oncol 2017 Dec

Contrary to prior findings, adding olaparib to paclitaxel failed to improve survival in patients with disease progression following chemotherapy.


Predicting Response to Immunotherapy in Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Rizvi H et al. J Clin Oncol 2018 Jan 16

Assessment of tumor mutation burden using targeted next-generation sequencing may be predictive of benefit from PD-1 and PD-L1 inhibitors.


Prolonged Adjuvant Aromatase Inhibitor Treatment for Early Breast Cancer

William J. Gradishar, MD reviewing Blok EJ et al. J Natl Cancer Inst 2018 Jan 1, Goldvaser H et al. J Natl Cancer Inst 2018 Jan 1, Pohlmann PR and Isaacs C. J Natl Cancer Inst 2018 Jan 1

Outcomes were not superior with 5 versus 2.5 years of extended letrozole therapy.


Prognosis of Monoclonal Gammopathy of Undetermined Significance

David Green, MD, PhD reviewing Kyle RA et al. N Engl J Med 2018 Jan 18

Overall survival was significantly shorter among MGUS patients than among a matched control population in a long-term follow-up study.


Prognosis for BRCA-Mutated Breast Cancer

William J. Gradishar, MD reviewing Copson ER et al. Lancet Oncol 2018 Jan 11

Survival is similar between BRCA mutation carriers versus those with sporadic disease.


Electrical Field Therapy for Glioblastoma

Roy E. Strowd, MD reviewing Stupp R et al. JAMA 2017 Dec 19

Adding tumor-treating electrical-field therapy to maintenance temozolomide chemotherapy significantly improved survival in patients with newly diagnosed glioblastoma.


Atezolizumab for Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Powles T et al. Lancet 2017 Dec 18, Massari F and Di Nunno V. Lancet 2017 Dec 18

Overall survival was not improved with the PD-L1 inhibitor atezolizumab versus chemotherapy in patients with highest PD-L1 expression.


Pembrolizumab for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Balar AV et al. Lancet Oncol 2017 Sep 26

First-line therapy demonstrated antitumor activity in a phase II study.


Restarting Adjuvant Endocrine Therapy for Breast Cancer

William J. Gradishar, MD reviewing He W et al. J Natl Cancer Inst 2017 Oct 01

Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.